利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.026 秒)

    DNA-PK inhibitors
    6.
    发明授权
    DNA-PK inhibitors 失效
    DNA-PK抑制剂

    公开(公告)号：US07402607B2

    公开(公告)日：2008-07-22

    申请号：US11231041

    申请日：2005-09-20

    申请人： Graeme Cameron Murray Smith ,  Niall Morrison Barr Martin ,  Keith Allan Menear ,  Marc Geoffrey Hummersone ,  Laurent Jean Martin Rigoreau ,  Roger John Griffin ,  Bernard Thomas Golding ,  David Richard Newell ,  Hilary Alan Calvert ,  Nicola Jane Curtin ,  Ian Robert Hardcastle ,  Kappusamy Saravanan

    发明人： Graeme Cameron Murray Smith ,  Niall Morrison Barr Martin ,  Keith Allan Menear ,  Marc Geoffrey Hummersone ,  Laurent Jean Martin Rigoreau ,  Roger John Griffin ,  Bernard Thomas Golding ,  David Richard Newell ,  Hilary Alan Calvert ,  Nicola Jane Curtin ,  Ian Robert Hardcastle ,  Kappusamy Saravanan

    IPC分类号： A61K31/381 ,  C07D333/76

    CPC分类号： C07D413/14 ,  C07D409/04 ,  C07D409/14

    摘要： A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(═O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(═O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R6 and R7 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and if Q is —NH—C(═O)—, —Y—X may additionally be selected from C1-7 alkyl.

    摘要翻译： 式I化合物及其异构体，盐，溶剂合物，化学保护形式及其前药，其中：R 1和R 2独立地选自氢，任选地 取代的C 1-7烷基，C 3-20杂环基或C 5-20-20芳基，或者可以一起形成 与它们所连接的氮原子一起形成具有4至8个环原子的任选取代的杂环; Q是-NH-C（-O） - 或-O-; Y是任选取代的C 1-5亚烷基; X选自SR 3或NR 4 R 5，其中R 3，R 3，R 3， 4和R 5独立地选自氢，任选取代的C 1-7 - 烷基，C 5-20-20芳基，或 C 3-20杂环基或R 4和R 5可以一起与它们所连接的氮原子一起形成一个 具有4至8个环原子的任选取代的杂环; 如果Q是-O-，X另外选自-C（-O）-NR 6 R 7，其中R 6和R 独立地选自氢，任选取代的C 1-7 - 烷基，C 5-20-20芳基或C 3-20 或者R 6和R 7可以与它们所连接的氮原子一起形成任选取代的杂环，其具有4个 至8个环原子; 并且如果Q是-NH-C（-O） - ，-Y-X可另外选自C 1-7烷基。

    Quinazolinone compounds
    8.
    发明授权
    Quinazolinone compounds 失效
    喹唑啉酮化合物

    公开(公告)号：US6156739A

    公开(公告)日：2000-12-05

    申请号：US362901

    申请日：1999-07-29

    申请人： Roger John Griffin ,  Alan Hilary Calvert ,  Jane Nicola Curtin ,  David Richard Newell ,  Bernard Thomas Golding

    发明人： Roger John Griffin ,  Alan Hilary Calvert ,  Jane Nicola Curtin ,  David Richard Newell ,  Bernard Thomas Golding

    IPC分类号： A61K31/675 ,  A61P35/00 ,  A61P43/00 ,  C07D239/91 ,  C07D403/10 ,  C07F9/6512 ,  A01N57/00 ,  C07F9/02

    CPC分类号： C07D239/91 ,  C07F9/65128

    摘要： Phosphate derivatives are disclosed of quinazolinone compounds having structural formula (I) or a pharmaceutically acceptable salt thereof, wherein X' represent hydroxyl, alkyl, alkoxy, or O--Z where Z is a phosphate or phosphate derivative; Y' represents hydrogen, alkyl or an optionally substituted aryl group or optionally substituted aralkyl group; and R' is hydrogen, alkyl, or CH.sub.2 --O--Z where Z is again a phosphate or phosphate derivative; subject to the proviso that if neither X' nor R' contains Z, Y' is an aryl or aralkyl group having an O--Z substituent therein with Z once again being a phosphate or phosphate derivative as hereinabove defined. These compounds are useful as prodrugs for providing active PARP inhibiting substances for medical use in conjunction with a cytotoxic drug or radiotherapy in order to increase the effectiveness of the latter, especially in connection with antitumor treatment. ##STR1##

    摘要翻译： 公开了具有结构式（I）的喹唑啉酮化合物或其药学上可接受的盐，其中X'代表羟基，烷基，烷氧基或O-Z，其中Z是磷酸酯或磷酸酯衍生物; Y'表示氢，烷基或任选取代的芳基或任选取代的芳烷基; 和R'是氢，烷基或CH 2 -O-Z，其中Z再次是磷酸酯或磷酸酯衍生物; 条件是如果X'和R'都不含Z，Y'是其中具有O-Z取代基的芳基或芳烷基，其中Z再次是如上所定义的磷酸酯或磷酸酯衍生物。 这些化合物可用作提供用于药物的活性PARP抑制物质与细胞毒性药物或放射疗法联合以提高后者的有效性，特别是与抗肿瘤治疗有关的前药。